Elizabeth Kennedy Rutledge

US Patent:

20040142387, Jul 22, 2004

Filed:

May 29, 2003

Appl. No.:

10/449741

Inventors:

Ake Lernmark - Seattle WA, US
Dong Luo - Kenmore WA, US
Armand MacMurray - Seattle WA, US
Ruth Ettinger - Seattle WA, US
Daniel Moralejo - Seattle WA, US
Elizabeth Rutledge - Lake Stevens WA, US

Assignee:

University of Washington - Seattle WA

International Classification:

G01N033/53
G01N033/567
C07K014/47

US Classification:

435/007200, 530/350000

Abstract:

GAD65 mutants which lack a C-terminal conformational epitope are disclosed. The GAD65 mutants can be used in diagnostic methods for detecting the presence of or risk of developing type 1 diabetes. Also disclosed are compositions relating to the Ian5 gene, including Ian5 polynucleotides, Ian5 polypeptides and antibodies thereto, and expression vectors, recombinant cells comprising the Ian5 polynucleotides, and genetically modified animal models. In particular, the compositions include those relating to truncated mutant Ian5 polypeptides lacking a significant portion of the C-terminus. Mutations in the Ian5 gene locus that result in a truncated Ian5 protein are associated with lymphopenia and type 1 diabetes in mammals. The compositions are useful, for example, in methods of screening for agonists or antagonists of Ian5 pathways, such as to identify candidate agents for diabetes drug development, or for developing gene therapy for type 1 diabetes or a related disorder. Also disclosed are diagnostic methods relating to Ian5 gene mutations.

US Patent:

6156303, Dec 5, 2000

Filed:

Jun 11, 1997

Appl. No.:

8/873168

Inventors:

David W. Russell - Seattle WA
Elizabeth A. Rutledge - Seattle WA

Assignee:

University of Washington - Seattle WA

International Classification:

A61K 4800
C12N 15864
C12N 1564
C12N 510

US Classification:

424 932

Abstract:

The present invention provides isolated adenovirus-associated viruses ("AAV"), including AAV isolates designated AAV3B and AAV6. The invention also provides nucleic acid molecules of AAV3B (SEQ ID NO: 1) or AAV6 (SEQ ID NO: 2), including DNA or RNA, and provides substantially purified polypeptides encoded by AAV3B or AAV6, as well as antibodies specific for such polypeptides. The invention also provides infectious AAV3B and AAV6 clones; AAV viral vectors, which can be hybrid AAV viral vectors; AAV vector plasmids; and AAV helper plasmids; each comprising at least a portion of an AAV3B (SEQ ID NO: 1) or AAV6 (SEQ ID NO: 2) nucleic acid molecule. The invention further provides host cells containing at least a portion of an AAV3B or AAV6 nucleic acid molecule and progeny cells derived therefrom, and provides non-human transgenic mammals having an AAV vector genome stably integrated in a chromosome. The invention also provides methods of producing a polypeptide or an RNA by expressing the polypeptide or the RNA from an AAV viral vector in a cell, and methods of treating a pathologic condition in a mammal, comprising transducing cells of the mammal with an AAV viral vector containing a heterologous nucleic acid sequence. The invention also provides AAV3B or AAV6 nucleotide sequences, which can be useful, for example, as probes for identifying the presence of AAV3B or AAV6 nucleic acids in a sample.